These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34883529)

  • 1. Determination of the efficacy rate and time-to-efficacy of subcutaneous immunotherapy in dogs with atopic dermatitis.
    Tham HL; Olivry T
    Vet Dermatol; 2022 Apr; 33(2):155-e44. PubMed ID: 34883529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis.
    Fischer NM; Rostaher A; Favrot C
    Vet Dermatol; 2020 Oct; 31(5):365-e96. PubMed ID: 32537789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
    van Amersfort K; Vernooij JCM; van der Lee A
    Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.
    Timm K; Mueller RS; Nett-Mettler CS
    Vet Dermatol; 2018 Apr; 29(2):123-e49. PubMed ID: 29327474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis.
    Kawano K; Mizuno T
    Vet Dermatol; 2017 Dec; 28(6):583-e141. PubMed ID: 28776792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2.
    Olivry T; Paps JS; Dunston SM
    Vet Dermatol; 2017 Apr; 28(2):183-e40. PubMed ID: 28261915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of subcutaneous allergen immunotherapy in atopic dogs: A retrospective study of 664 cases.
    Fennis EEM; van Damme CMM; Schlotter YM; Sinke JD; Leistra MHG; Bartels RT; Broere F
    Vet Dermatol; 2022 Aug; 33(4):321-e75. PubMed ID: 35635279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy.
    Griffin CE; Hillier A
    Vet Immunol Immunopathol; 2001 Sep; 81(3-4):363-83. PubMed ID: 11553398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis.
    Hobi S; Mueller RS
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2014; 42(3):167-73. PubMed ID: 24920143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of rush immunotherapy in the management of canine atopic dermatitis-230 cases.
    Weitzer T; Mueller R
    Vet Dermatol; 2023 Oct; 34(5):385-392. PubMed ID: 37157908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 10 and transforming growth factor-beta 1 plasma levels in atopic dogs before and during immunotherapy.
    Martini F; Rostaher A; Favrot C; Fischer N
    Vet Rec; 2022 Jun; 190(12):e1270. PubMed ID: 34939678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs.
    Mueller RS; Zablotski Y; Baumann K; Boehm T; Kasper B; Klinger C; Monke M; Udraite-Vovk L; Weitzer T; Gedon NKY
    Vet Dermatol; 2023 Apr; 34(2):91-98. PubMed ID: 36424528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study.
    Colombo S; Hill PB; Shaw DJ; Thoday KL
    Vet Dermatol; 2005 Jun; 16(3):162-70. PubMed ID: 15960629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of allergen-specific immunotherapy in atopic dogs with Malassezia hypersensitivity: a retrospective study of 16 cases.
    Åberg L; Varjonen K; Åhman S
    Vet Dermatol; 2017 Dec; 28(6):633-e157. PubMed ID: 28748560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shortened immunotherapy dose-escalation saves time, but is it safe? A case-control study comparing the rates of adverse reactions between conventional and fast-escalation subcutaneous immunotherapy protocols during the induction phase.
    Herrmann I; Loft KE; Olivry T
    Vet Dermatol; 2020 Dec; 31(6):454-e120. PubMed ID: 32940395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells.
    González JL; Zalve V; Fernández-Caldas E; Cases B; Subiza JL; Casanovas M
    Vet Dermatol; 2018 Oct; 29(5):449-e152. PubMed ID: 30183126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study.
    Mueller RS; Veir J; Fieseler KV; Dow SW
    Vet Dermatol; 2005 Feb; 16(1):61-8. PubMed ID: 15725107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis].
    Fischer N; Rostaher A; Favrot C
    Schweiz Arch Tierheilkd; 2016 Sep; 158(9):646-652. PubMed ID: 27655164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis.
    Zhou J; Chen S; Song Z
    Allergy Asthma Proc; 2021 Mar; 42(2):e47-e54. PubMed ID: 33685566
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.
    Nahm DH; Kim ME; Kwon B; Cho SM; Ahn A
    Yonsei Med J; 2016 Nov; 57(6):1420-6. PubMed ID: 27593870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.